Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NYSE:MNK

Mallinckrodt (MNK) Stock Price, News & Analysis

Mallinckrodt logo

About Mallinckrodt Stock (NYSE:MNK)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.14
$0.75
52-Week Range
N/A
Volume
39,227 shs
Average Volume
2.62 million shs
Market Capitalization
$1.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.

Receive MNK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mallinckrodt and its competitors with MarketBeat's FREE daily newsletter.

MNK Stock News Headlines

Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
See More Headlines

MNK Stock Analysis - Frequently Asked Questions

Mallinckrodt plc (NYSE:MNK) announced its quarterly earnings results on Tuesday, August, 4th. The company reported $1.89 EPS for the quarter, beating the consensus estimate of $1.34 by $0.55. Mallinckrodt's revenue was down 14.9% compared to the same quarter last year.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mallinckrodt investors own include Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Micron Technology (MU), Endo International (ENDP), Bausch Health Companies (BHC), Meta Platforms (META) and Gerdau (GGB).

Company Calendar

Last Earnings
8/04/2020
Today
5/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NYSE:MNK
Fax
N/A
Employees
2,700
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$47.48 per share
Price / Book
N/A

Miscellaneous

Free Float
13,131,000
Market Cap
$1.58 million
Optionable
Not Optionable
Beta
N/A
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NYSE:MNK) was last updated on 5/31/2025 by MarketBeat.com Staff
From Our Partners